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Magnetic resonance imaging (MRI)
Animal models
Guidelines
A B S T R A C T
Magnetic resonance imaging (MRI) is the most important paraclinical tool for assessing drug response in mul-
tiple sclerosis (MS) clinical trials. As such, MRI has also been widely used in preclinical research to investigate
drug efficacy and pathogenic aspects in MS animal models. Keeping track of all published preclinical imaging
studies, and possible new therapeutic approaches, has become difficult considering the abundance of studies.
Moreover, comparisons between studies are hampered by methodological differences, especially since small
differences in an MRI protocol can lead to large differences in tissue contrast. We therefore provide a com-
prehensive qualitative overview of preclinical MRI studies in the field of neuroinflammatory and demyelinating
diseases, aiming to summarize experimental setup, MRI methodology, and risk of bias. We also provide estimates
of the effects of tested therapeutic interventions by a meta-analysis. Finally, to improve the standardization of
preclinical experiments, we propose guidelines on technical aspects of MRI and reporting that can serve as a
framework for future preclinical studies using MRI in MS animal models. By implementing these guidelines,
clinical translation of findings will be facilitated, and could possibly reduce experimental animal numbers.
1. Introduction
A growing number of large cooperatives, including the Alzheimer's
Disease Neuroimaging Initiative (ADNI) and the Human Connectome
Project (HPC) (Petersen et al., 2010; Van Essen et al., 2013) aim to
standardize reporting on neuroimaging in humans. Whereas standar-
dized reporting on neuroimaging in clinical research — including the
use of magnetic resonance imaging (MRI) as a fundamental tool in di-
agnosis and monitoring of multiple sclerosis (MS) — has received much
attention, no such attempts have been made in preclinical neuroima-
ging research. This gap is surprising since MRI is also widely used in
preclinical research to screen for drug efficacy and to investigate pa-
thogenic aspects in animal models, especially in MS animal models, in
which both inflammatory and demyelinating pathology are readily
detectable using MRI. One concern is that differences in experimental
MRI scanning and reporting on technical imaging details can impede
comparisons between studies. A comprehensive reporting of
methodological details is also key for potential replication of findings
(Kilkenny et al., 2010) — an issue that is receiving a great deal of at-
tention in preclinical research (Justice and Dhillon, 2016; Kilkenny
et al., 2010; Steward and Balice-Gordon, 2014). Thus, improved re-
porting of methodological imaging details can maximize the avail-
ability and utility of the information gained from every animal ex-
periment, which can ultimately prevent unnecessary animal
experiments in the future. Finally, keeping track of the abundance of
preclinical MS neuroimaging studies so far published has proven diffi-
cult.
Therefore, we set out to provide a comprehensive overview of
preclinical MRI studies in the field of neuroinflammatory and demye-
linating diseases, summarizing experimental setup, MRI methodology,
and risk of bias. Through a meta-analysis, we also investigated the ef-
ficacy of assessed therapeutic approaches using MRI outcome measures
and histological measures of disease activity in MS animal models. In
order to increase standardization of experiments, we propose minimal
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reporting guidelines on technical aspects and experimental setup for
future preclinical MRI studies, with the goal of improving successful
translation of preclinical findings for potential therapeutic interven-
tions for MS.
2. Materials and methods
This systematic review summarizes preclinical studies assessing
therapies and/or pathogenic aspects of MS in corresponding animal
models using MRI. The inclusion criteria and method of analysis were
specified in advance and documented in a protocol, which was pub-
lished on PROSPERO (registration number: CRD42019134302). We
used the Preferred Reporting Items for Systematic Reviews and Meta-
Analysis (PRISMA) Guidelines (Moher et al., 2015).
2.1. Search strategy and paper selection
A comprehensive search string to identify publications assessing
MRI in MS animal models was generated. The following databases were
searched for matches: EMBASE, go3R, Medline, PubMed, Scopus, and
Web of Science (last search 01 May 2020). See Supplementary search
string for the exact string. All animal species, publication dates, and
languages were included in the database search.
Publications were included in this systematic review if they met the
following inclusion criteria: (1) the publication was an original peer
reviewed full publication that published unique data; and, (2) since MS
animal models are generally defined by neuroinflammatory (e.g. ex-
perimental autoimmune encephalomyelitis or Theiler’s murine en-
cephalomyelitis) and/or demyelinating pathology (e.g. cuprizone or
lysolecithin), the publication used an animal model with a neuroin-
flammatory/demyelinating pathological substrate in conjunction with
any MRI outcome.
Publications were included in the meta-analysis if they met the
following inclusion criteria in addition to the ones listed above: (3) the
publication contained at least one adequate control group (i.e. vehicle
or no treatment); (4) an outcome measure related to MRI was used; and
(5) the publication provided an effect measure, animal numbers, and a
measure of variability for the respective experimental groups.
Publications were screened for relevance by one reviewer. Reviews
were excluded but used as a source for potential studies and for dis-
cussion.
2.2. Data extraction
The following study characteristics were extracted from the full-
texts by two independent reviewers: (1) parameters on model organ-
isms and disease model: type of animal model, tested intervention,
application regimen, species, strain, sex, housing conditions, weight,
and number of animals per group; (2) parameters on MRI scanning:
anesthesia, technical details on MRI scanner (supplier, coils, gradients,
magnetic field strength), technical details on MR imaging parameters
(pulse sequence, echo/repetition time, field of view, matrix size, and
others), contrast agent type, and dosage. As study outcome measures,
we extracted the mean and variance (standard deviation [SD]) or
standard error of the mean [SEM]) of all available MRI outcome
parameters. BVI checked if all data were extracted correctly.
Disagreement between the two reviewers was solved by jointly asses-
sing the data in the publications and coming to a consensus. The inter-
rater agreement was 71% for MRI outcomes.
When possible, data were extracted from text or tables; if not, data
were extracted from graphs using universal desktop ruler software (AVP
Software Development, USA). When the group size was reported as a
range (e.g., 6–7), the mean number of animals was used in our analysis
(e.g. 6–7 = 6.5).
2.3. Quality assessment
We scored the risk of bias according to a five-item checklist derived
from the consensus statement ‘Good laboratory practice’ in the mod-
elling of stroke (Macleod et al., 2009): implementation in the experi-
mental setup of any measure of randomization, any measure of
blinding, prior sample size calculation, statement on animal welfare,
and statement of a potential conflict of interest. For each of these items,
a ‘yes’, a ‘NR’ (not reported), or a ‘no’ was scored. As a sixth item, we
also scored whether the study was in accordance with the ARRIVE
guidelines (Kilkenny et al., 2010).
2.4. Meta-analysis
Data were analyzed using the software Comprehensive Meta-
Analysis (CMA, version 3.0). Different studies used different scales to
measure the same outcome; thus, we calculated the Hedges’ g stan-
dardized mean difference (SMD) — the mean of the experimental group
minus the mean of the control group divided by the pooled SDs of the
two groups — instead of the raw mean difference.
In order to adequately represent weight of individual experiments in
the meta-analysis, control groups were adjusted in case they served for
more than one experimental group. In that case, the number of ob-
servations in that control group was divided by the number of experi-
mental groups served.
Individual SMDs were subsequently pooled to obtain an overall
SMD and 95% confidence interval. Since we did not expect one true
underlying effect of all the meta-analyzable studies, we used the random
effects model [14], which takes into account the precision of individual
studies and the variation between studies and weighs each study ac-
cordingly.
Sources for heterogeneity were explored using I2 to describe the
percentage of the variability in the effect estimates that is due to het-
erogeneity rather than sampling error (Higgins and Thompson, 2002).
We expected the variance to be comparable within the subgroups (i.e.,
the pooled treatments); therefore, we assumed a common across-study
variance across subgroups. No sub-subgroup analyses were calculated
due to low number of experiments per therapeutic approach.
We used funnel plots, Trim and Fill analysis, and Egger regression to
assess potential publication bias. SMDs may cause funnel plot distor-
tion, thus, we plotted the SMD against n1/ , a sample size-based pre-
cision estimate (Zwetsloot et al., 2017).
3. Results
3.1. Study selection process
Fig. 1 depicts the flow chart of the study selection process (Moher
et al., 1999). A search string for MS animal models and MRI was used in
conjunction with an animal filter (de Vries et al., 2014). A total of 9079
publications were retrieved via EMBASE, Medline, PubMed, Scopus,
and Web of Science, of which 4112 publications remained after dedu-
plication. After initial screening of titles and abstracts, 499 publications
were included in the full-text search. Of these, 300 unique publications
met our inclusion criteria for the synthesis on experimental methods
(Supplementary reference list). Of these, 67 unique publications in-
vestigated a potential MS therapy, whereas 49 unique publications
contained quantitative structural MRI data and could therefore be used
for the quantitative synthesis on therapy effect in MRI (meta-analysis).
The remainder was excluded according to the criteria listed in Fig. 1.
The first report using MRI in an MS animal model was published in
1985 (Stewart et al., 1985). It showed that MRI lesions were apparent in
primate brains prior to experimental autoimmune encephalomyelitis
(EAE) symptom onset. The first report using an MS animal model to
assess a therapy for its remyelinating potential in vivo and meeting our
inclusion criteria, however, was only published in 1994 (Namer et al.,
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1994). Thus, all studies included in the meta-analysis were published
between 1994 and 2020.
3.2. Description of the included studies
3.2.1. Model organisms and disease models
The characteristics of the 300 included publications are shown in
Supplementary Table 1. Study characteristics are summarized in Fig. 2.
Most of the publications used mice as an experimental model organism
(167 publications, 56%, Fig. 2A), followed by rats (77, 26%). Marmo-
sets (23, 8%), guinea pigs (15, 5%), macaques (13, 4%), dogs
(2,< 1%), mini pigs (1,< 1%), rhesus monkeys (1,< 1%) and swines
(1,< 1%) were less commonly used. Mice with C57Bl/6 background
(114, 68%) were most commonly used, followed by SJL (35, 21%).
Lewis was the most commonly used rat strain (44, 57%). The majority
of publications used animals with female sex (152, 51%) as compared
to male sex (57, 19%). Twenty-eight publications (9%) used both sexes,
and 63 publications (21%) did not report the sex of their model or-
ganism. In many publications, no information on animal weight (197,
66%), age (97, 32%) or animal housing (172, 57%) was available. Fifty-
six publications (19%) did not report the total number of animals they
used.
A wide variety of animal models has been used to mimic MS pa-
thology in the model organisms: 191 publications used EAE (64%,
Fig. 2A), followed by cuprizone (54, 18%), Theiler’s murine en-
cephalomyelitis (TMEV, 11, 4%), lysolecithin (9, 3%), targeted EAE (7,
2%), chronic hyponatremia (3, 1%), intracerebral cytokine injection (3,
1%), lipopolysaccharide (3, 1%), delayed type hypersensitivity
(2,< 1%), optic neuritis (upon EAE induction, 2,< 1%), spontaneous
Japanese macaque encephalomyelitis (2,< 1%), ethidium bromide
(2,< 1%), and vector-based cytokine overexpression (1,< 1%). Seven
publications (2%) used two MS animal models. One publication (< 1%)
did not report which animal model was used.
3.2.2. Assessed therapies
A total of 44 different therapies (47 different therapeutic ap-
proaches) were investigated in 49 of the publications. The assessed
therapies are listed in Supplementary Table 2.
3.2.3. Imaging parameters
The most common anesthesia for the imaging was isoflurane (141,
47%, Fig. 2B) in concentrations between 1 and 5 vol%, followed by
ketamine/xylazine (40, 13%).
Regarding MRI scanner, 167 publications used a Bruker MRI system
(56%, Fig. 2B), followed by Varian (38, 13%), General Electric (22,
7%), Siemens (15, 5%), Agilent (11, 4%), Philips (9, 3%) and Oxford
Instruments (7, 2%). SMIS (3), Picker (3), Hitachi (1), SISCO (1), Rapid
Biomedical (1), Technicare (1) and a scanner from the National High
Magnetic Field Laboratory (NHMFL, 1) were less commonly used.
Twenty publications (7%) did not report which MRI system they used.
Most publications used a magnetic field strength of 7 T (T; 90, 30%),
followed by 4.7 T (72, 24%), 9.4 T (47, 16%), 1.5 T (26, 9%), and
11.7 T (14, 5%). The lowest field strength was 0.15 T in two publica-
tions from 1985 and 1991 (Stewart et al., 1991, 1985). The highest field
strength was 21.1 T in a publication from 2019 (Waiczies et al., 2019).
Relatively few publications reported on technical specifications about
the used gradient system (77, 26%), magnet (103, 34%), or receiver coil
(189, 63%).
Whereas in vivo imaging only was performed in 232 publications
(77%, Fig. 2B), ex vivo imaging only was performed in 36 publications
(12%). 32 publications (11%) acquired both in vivo and ex vivo MR
images, respectively. Brain only was imaged by most publications (228,
Fig. 1. Prisma flow chart of the study selection process (Moher et al., 1999). Deduplication refers to removing identical studies found in multiple medical databases
(e.g. same references in EMBASE and MEDLINE). Four duplicate studies were removed in the eligibility stage. Abbreviations: MRI, magnetic resonance imaging; MRS,
magnetic resonance spectroscopy; MS, multiple sclerosis.
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76%) followed by spinal cord only (37, 12%). Both brain and spinal
cord were imaged by 26 publications (9%). 86 publications acquired
longitudinal neuroimaging (37% of in vivo imaging publications). The
longest imaging follow-up time was 12 months.
A total of 709 MRI sequences were applied in all 300 publications.
Commonly used sequences included fast or Turbo Spin Echo/Rapid
Acquisition with Refocused Echoes (TSE/RARE) (146, 21%), conven-
tional spin echo (101, 14%), Fast Low Angle Shot (FLASH) (62, 9%),
and conventional gradient echo sequences (40, 6%). No sequence in-
formation was reported in 179 sequences (25%). For most sequences,
both an echo time (TE) and a repetition time (TR) was reported (609,
86%). In contrast, there was a general lack of information on other
basic imaging parameters: information on receiver bandwidth was re-
ported for 21 sequences (3%), flip angle on 150 sequences (21%), field
of view on 401 sequences (57%), and matrix size on 451 sequences
(64%).
Out of 709 MRI sequences, mostly T2-weighted images were ac-
quired (215, 30%), followed by T1-weighted (163, 23%), T2*-weighted
(55, 8%), and proton density-weighted (30, 4%). Sixty-two publications
acquired diffusion-weighted images (DWI, 21%), and 35 publications
acquired magnetization transfer images (MTI, 12%).
Of 62 publications acquiring DWI, 27 reported the maximum b
value (44%). B values ranged from 50 to 3000 s/mm2. Twenty-five
publications reported the pulse duration (δ, 40%) and the time between
the pulses (Δ, 40%). Only a few publications reported the number of
directions (11 publications, 18%) or the diffusion gradient strength (9
publications, 15%). Of note, more than 1/3 of publications using DWI
were released in the three years prior to our search cutoff date.
3.2.4. Contrast agent
MRI scans were enhanced by various contrast agents in 126 pub-
lications (42%, Fig. 2B). Some publications used more than one contrast
agent. The most commonly used contrast agent was gadolinium-DTPA
(Gd-DTPA, Magnevist), which was used in 62 publications (21%), fol-
lowed by Gd-DOTA (Dotarem; 13, 4%), gadodiamide (Omniscan; 4,
1%), and gadoteridol (Prohance; 4, 1%). Altogether, 93 publications
(31%) used Gd-based contrast agents, followed by iron-based contrast
agents (43, 14%), especially iron oxides such as SPIO or USPIO. Man-
ganese- (5 publications) and magnesium-based (1 publication) contrast
agents were less commonly used.
4 out of 126 respective publications (67%) reported on the con-
centration of Gd-based contrast agents. Most of these publications used
concentrations between 0.2 and 0.5 mmol/kg (62, 49%).
3.2.5. Study quality and risk of bias
Poor reporting in preclinical studies is a known issue, and therefore
many items of commonly used risk of bias tools are scored as unclear
risk of bias (Hooijmans et al., 2014). We therefore scored the risk of
bias according to a five-item checklist derived from the consensus
statement ‘Good laboratory practice’ in the modelling of stroke
(Macleod et al., 2009). These items were also scored in a comparable
study in EAE (Vesterinen et al., 2010) and in a study of toxic demye-
lination models (TD) (Hooijmans et al., 2019). Compliance with animal
welfare regulations or an approved animal license were reported in
80% of cases (EAE: 32%, TD: 58%). Blinding of the experiment at any
level was reported in 29% of publications (EAE: 16%, TD: 38%). Due to
the experimental setup, one publication (< 1%) was not able to blind
their researchers, and this was explicitly reported. A statement about
conflict of interest was reported in 35% of publications (EAE: 6%, TD:
38%). Thirteen percent of publications reported randomization at any
level (EAE: 9%, TD: 5%). Four publications (1%) reported a prior
sample size calculation (EAE:< 1%, TD: 2%). These findings are
summarized in Fig. 2C.
Finally, as a sixth item, we checked whether the publication was in
accordance with the ARRIVE guidelines — an initiative to improve the
reporting standard of animal research (Kilkenny et al., 2010). Three
Fig. 2. Bar plots demonstrating proportional study characteristics (A and B) and
risk of bias assessment (C) of all 300 eligible studies. (A) Proportional study
characteristics on species, animal sex, and multiple sclerosis animal model. (B)
Proportional study characteristics on type of anesthesia for imaging, magnetic
resonance imaging (MRI) scanner supplier, field strength of MRI scanner,
scanned central nervous system region(s), and use of contrast agent. The top
portion of the bar always represents the remaining pooled categories per
characteristic or the proportion of studies who did not report on that particular
study characteristic. (C) Risk of bias assessment of eligible studies using a six-
item checklist (animal welfare reporting, blinding of experiments, statement of
a potential conflict of interest, randomization in experimental setup, prior
sample size calculation, study in accordance with ARRIVE guidelines (Kilkenny
et al., 2010; Macleod et al., 2009)). For each of these items, ‘yes’, ‘NR’ (not
reported), or ‘no’ was scored. Except for the item animal welfare statement, the
majority of studies have unclear risk of bias (i.e., not reported; orange bar).
Abbreviations: Bru, Bruker; Cup, cuprizone; EAE, experimental autoimmune
encephalomyelitis; Gd, gadolinium; Iso, isoflurane; K/X, ketamine-xylazine;
marm, marmosets; NR, not reported; Var, Varian; SC, spinal cord. (For inter-
pretation of the references to colour in this figure legend, the reader is referred
to the web version of this article.)
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publications reported being in accordance with the ARRIVE guidelines
(1%, Fig. 2C).
3.3. Meta-analysis
3.3.1. Magnetic resonance imaging as outcome
The 49 publications in the meta-analysis included studies containing
a total of 95 different experiments. Different MRI outcome measures
were used to measure therapy efficacy. Out of 95 experiments, T2 or
contrast-enhancing lesion load were most commonly used as MRI
readout (26 experiments, 27% and 24 experiments, 25%, respectively),
followed by DWI (20 experiments, 21%), MTI (7 experiments, 7%), T1
lesion load (4 experiments, 5%), and brain atrophy measure (5 ex-
periments, 4%).
Pooling the individual effect sizes of all therapies in our meta-ana-
lyses showed that the therapies described in the literature had a ben-
eficial effect on MRI outcomes (e.g. volume of T2 brain lesion load,
standardized mean difference (SMD): 1.24, 95% CI: [1.06, 1.34],
p = 0.021, Table 1). The overall heterogeneity between the studies was
moderate (I2 = 37%).
In order to obtain a more detailed overview of the efficacy of the
various therapies included in this review, we also analyzed the effect of
the 47 different therapeutic approaches for their impact on MRI out-
comes separately. Twenty-eight therapeutic approaches led to a sig-
nificant improvement of MRI outcomes (Fig. 3). For the remaining 19
therapeutic approaches, no statistically significant results were found.
Of note, in most cases, only one study was available per therapeutic
approach. The median sample size [interquartile range, IQR] was 7
[5–10] for the treatment groups and 6 [4–8] for the control groups.
3.3.2. Histological markers of (re-)myelination as outcome
In total, 25 publications also assessed the remyelinating potential of
therapeutic approaches. The most commonly used staining method to
assess (re-)myelination was Luxol fast blue (LFB, 11 publications, 44%),
followed by immunohistochemistry/-fluorescence stainings (for MBP,
PLP, or Fluoromyelin; 8 publications, 32%) and electron microscopy (5
publications, 20%), and. Cyanin staining was used in one publication
(4%).
Pooling the individual effect sizes of all therapies in our meta-ana-
lyses showed that the therapies described in the literature had a ben-
eficial effect on histological outcomes of (re-)myelination (e.g. number
of thinly myelinated axons in electron microscopy, SMD: 1.72, 95% CI:
[1.09, 2.30], p = 0.014 Table 1). The overall heterogeneity (Higgins
and Thompson, 2002) between the studies was high (I2 = 80%),
however, reflecting the anticipated differences between interventions,
models used, and study design.
In order to obtain a more detailed overview of the efficacy of the
various therapies included in this meta-analysis, we also analyzed the
effect of the 24 different therapeutic approaches for their impact on (re-
)myelination histology markers separately (with the corresponding
method to assess (re-)myelination in square brackets). Seven
therapeutic approaches led to a significant improvement of histological
outcomes of (re-)myelination (glatiramer acetate/salirasib [LFB], ade-
novirus expressing IL-1β [AdIL-1β] [MBP], triiodothyronine [electron
microscopy], sildenafil [electron microscopy], salirasib [LFB], normo-
baric oxygen therapy [LFB], and olesoxime [electron microscopy];
Supplementary Fig. 1). For the remaining 17 therapeutic approaches,
no statistically significant results were found. The median sample size
[IQR] was 7 [5.38–9.5] for the treatment groups and 5.25 [3–7.25] for
the control groups.
3.3.3. Histological markers of neuroinflammation as outcome
In total, 17 publications also assessed the anti-inflammatory/im-
munomodulatory potential of therapeutic approaches. The most com-
monly used method to assess neuroinflammation was im-
munohistochemistry/-fluorescence (for CD3, ED1, Iba1, CD20, and/or
Ox22; 10 publications, 59%). Hematoxylin and eosin staining was less
commonly used (7 publications, 31%).
Pooling the individual effect sizes of all therapies in our meta-ana-
lyses showed that the therapies described in literature had a beneficial
effect on histological outcomes of neuroinflammation (e.g. number of
inflammatory CD3 + cells within parenchymal lesions, SMD: 1.20, 95%
CI: [0.93, 1.55], p = 0.019 Table 1). The overall heterogeneity between
the studies was substantial (I2 = 61%).
In order to obtain a more detailed overview of the efficacy of the
various therapies included in this meta-analysis, we also analyzed the
effect of the 18 different therapeutic approaches for their impact on
inflammatory histology markers separately (with the corresponding
method to assess inflammation in square brackets). Ten therapeutic
approaches led to a significant improvement of histological outcomes of
neuroinflammation (AdIL-1β [ED1], 7D8 [H&E], CXCR7 antagonist
[CD3], ICAM-1 antibody [CD3], CSF-1 receptor kinase inhibitor [Iba1],
CT301 [H&E], VLA-4 antibody [ED1], Interleukin-11R alpha Fc [CD4],
IL anti-12p40 [H&E], and fingolimod [Ox22]; Supplementary Fig. 2).
For the remaining 8 therapeutic approaches, no statistically significant
results were found. The median sample size [IQR] was 6 [5–7.5] for the
treatment groups and 5 [4–6] for the control groups.
3.3.4. Histological markers of neurodegeneration as outcome
In total, 5 publications also assessed the neuroregenerative/-pro-
tective potential of therapeutic approaches. Immunohistochemistry/-
fluorescence for neurofilament or SMI32 were used by 2 publications
each.
Pooling the individual effect sizes of all therapies in our meta-ana-
lyses showed that the therapies described in the literature had a positive
effect on histological outcomes of neurodegeneration (e.g. number of
SMI-positive axons within neuro-inflammatory lesions, SMD: 0.81, 95%
CI: [0.10, 1.51], p = 0.044, Table 1). The overall heterogeneity be-
tween the studies was substantial (I2 = 61%).
In order to obtain a more detailed overview of the efficacy of the
various therapies included in this meta-analysis, we also analyzed the
effect of the 5 different therapeutic approaches for their impact on
Table 1
Summary of outcome parameters used in studies assessing therapeutic approaches in MS animal models. Not all studies reported the sex of the used animals.
Abbreviations: Cup, cuprizone; EAE, experimental autoimmune encephalomyelitis; MRI, magnetic resonance imaging; SMD, standardized mean difference.).
Outcome Therapeutic approaches tested Model Sex Species Overall SMD [95% CI] and p value I2 (%)
EAE Cup Other F M Mice Rats Other
MRI 47 (95 experiments) 66 17 12 63 21 42 28 25 1.24 [1.06, 1.34]
p = 0.021
37
(Re-) myelination 25 (27 experiments) 14 8 5 17 7 11 8 8 1.72 [1.09, 2.30]
p = 0.014
80
Neuroinflammation 18 (20 experiments) 13 4 3 9 5 7 6 7 1.20 [0.93, 1.55]
p = 0.019
61
Neurodegeneration 5 (5 experiments) 2 3 0 3 0 5 0 0 0.81 [0.10, 1.51]
p = 0.044
61
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neurodegeneration histology markers separately (with the corre-
sponding method to assess inflammation in square brackets). Only one
therapeutic approach (olesoxime [Neurofilament]) led to a significant
improvement of histological outcomes of neurodegeneration
(Supplementary Fig. 3). For the remaining 4 therapeutic approaches, no
statistically significant results were found. The median sample size
[IQR] was 4.5 [3.75 – 5.25] for the treatment groups and 4.5 [4–5.25]
for the control groups.
3.3.5. Correlation analysis
We next asked how well MRI outcome measures correlate with
histological markers of (re-)myelination or neuroinflammation. For
this, we plotted the SMDs of the MRI outcomes against the SMDs of
these histological outcomes. A positive correlation was found for any
non-contrast-enhanced MRI outcomes (i.e. structural T1-weighted/T2-
weighted and MTI measures as well as DWI measures) and measures of
(re–)myelination (Fig. 4A). SMDs of MRI outcomes showed no corre-
lation to neuroinflammation (Fig. 4B), Only 5 studies histologically
assessed neurodegeneration. Hence, we did not assess correlation.
3.3.6. Publication bias
In order to assess publication bias, we visually inspected the funnel
plot and calculated Egger’s regression. The funnel plot is a graphical
representation of trial size plotted against the reported effect size. An
uneven scattering on both sides of the summary effect size indicates
publication bias. Visual inspection of the funnel plot indicated the
presence of publication bias for MRI data (Fig. 5). This finding was
supported by Egger’s regression showing statistically significant evi-
dence for small study effects (p = 0.001).
4. Discussion
MRI is widely used in preclinical research to investigate putative
therapeutic approaches or pathogenic aspects in MS animal models.
Tracking the large number of published studies in this field has proven
difficult, however. In order to obtain an overview of these studies, we
systematically reviewed methodological details of preclinical studies
using MRI in MS animal models. Furthermore, a meta-analysis on
therapeutic approaches provides evidence for a solid correlation be-
tween MRI outcomes measures and histological measures of (re-)mye-
lination.
4.1. Risk of bias and reporting of methodological details
Accumulating evidence suggests low reproducibility rates in life
sciences (Justice and Dhillon, 2016), including neuroscience (Steward
and Balice-Gordon, 2014). A recent report indicates that, in the United
States alone, the cumulative prevalence of irreproducible preclinical
research exceeds 50% with an approximate cost of $28 billion/year
(Freedman et al., 2015). An insufficient reporting of experimental de-
tails in (pre-)clinical research can contribute to this lack of reproduci-
bility (Carp, 2012; Collins and Tabak, 2014). This problem is
Fig. 3. Forest plot of the included studies for MRI
outcomes. The diamond indicates the global esti-
mate and the whiskers its 95% confidence interval
(CI). The numbers listed after each therapy are: the
exact effect size with its 95% CI, the number of in-
cluded studies for a certain intervention (ns), the
total number of treated animals (nt) and control
animals (nc). The capital letters in round brackets
indicate whether the corresponding therapy has also
been tested for (re-)myelination (M), inflammation
(I) and/or neurodegeneration (N). The gray bar in-
dicates the 95% CI of the overall effect size. The
dotted line indicates an SMD of 0, i.e. studies with
whiskers which overlap this dotted line do not show
statistically significant SMDs between therapy and
control group. Also consider Supplementary
Figs. 1–3 for effect on (re-)myelination, inflamma-
tion and/or neurodegeneration. References are
provided in the Supplementary information.
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particularly apparent in MRI research, where small differences in
imaging protocol can lead to large differences in tissue contrast (Amiri
et al., 2018). Therefore, a detailed and accurate reporting of the used
methodology and results is key for future reproducibility of findings
from MRI studies and, more importantly, successful translation of
preclinical findings to clinical trials. Reduction of methodologically
inappropriate animal experiments could also ultimately reduce animal
numbers.
Estimating the risk of bias in our included publications, by scoring
whether measures to avoid bias were reported in six separate domains,
suggests an overall high risk of bias of the included studies, albeit in the
range of other published studies in the field (Hooijmans et al., 2019;
Vesterinen et al., 2010). It has been shown that studies that report on
measures to avoid bias, such as blinding of experimenters, yield sub-
stantially lower efficacy estimates (Macleod et al., 2008; Vesterinen
et al., 2010). Thus, it is highly recommended to include such measures
to the experimental design of any planned study.
Results from our systematic review show that an abundance of
different species and MS animal models has been used in conjunction
with MRI. Many studies have not reported on key methodological de-
tails of the experimental setup, e.g. 21% of all studies did not include
information on the sex of used animals and 19% of all studies did not
report the total number of studied animals. Guidelines for reporting
experiments involving animals have been published to tackle this pro-
blem (Kilkenny et al., 2010; Landis et al., 2012); they are still in-
sufficiently implemented to scientific practice, however (Baker et al.,
2014) (only 3 out of 300 publications reported of being in accordance
with the ARRIVE guidelines in our systematic review).
4.2. Minimal reporting guidelines
While the overall reporting on technical details regarding MRI
system and image acquisition was reasonable, some important metho-
dological details were seldom reported: many studies did not report on
gradient system, receiver bandwidth, flip angle magnitude, field of
view, matrix size or gradient strength, and number of directions in DWI.
There was also a high variability on which technical aspects were re-
ported and which were omitted. The poor reporting and the variability
in reporting are due to a lack of reporting guidelines. Whereas such
reporting guidelines for general aspects of preclinical animal research
(Kilkenny et al., 2010) or clinical trials (Moher et al., 2001) have been
proposed, no such guidelines are available for preclinical neuroimaging
studies. Thus, based on the findings in this review and our experience
with neuroimaging in animals, we propose minimal reporting guide-
lines (Table 2). The reporting suggestions are grouped according to
experimental steps, i.e. details on the MRI system, details on animal
anesthesia, details on sequence(s), details on contrast media (if ap-
plicable), and details on ex vivo imaging (if applicable). Even though we
did not include other disease models to our analysis, these guidelines
could be applied to any preclinical neuroscience research using MRI.
We also request referees and journal editors to scrutinize papers for
these details. A complete reporting of relevant information is key for a
potential replication of findings (Kilkenny et al., 2010).
4.3. Results from the meta-analyses
The meta-analysis for the MRI outcomes showed that therapies
tested in MS animal models had an overall beneficial effect on the
model disease course. The same is true for the outcomes (re-)myelina-
tion, neuroinflammation, and neurodegeneration. However, the effect-
size summaries and the therapy effect sizes should be interpreted with
caution, due to mostly small study sample sizes,differences in study
design characteristics, and overall low numbers of studies. They should
therefore not be used as rank order of potency.
Interestingly, there was a statistically significant positive correlation
between SMDs from the non-contrast-enhanced MRI outcomes and
histological measures of (re-)myelination. This suggests that non-con-
trast enhanced MRI outcomes reflect the underlying (re-)myelination
status reasonably well. Surprisingly, despite the relative success of
therapeutic development to modulate inflammation, our data did not
support a significant correlation between MRI outcomes and histolo-
gical outcomes of neuroinflammation. There were also too few studies
available to do subgroup analysis for specific imaging outcomes such as
contrast-enhancing lesions. More studies are thus needed to address
whether there is a correlation between specific imaging findings and
underlying histopathology in MS and/or corresponding animal models.
This holds particularly true for measures of neurodegeneration: only
four publications concomitantly assessed histological measures of
Fig. 4. Correlation analysis between standardized mean difference (SMD) of the
MRI outcomes and histological markers of (re-)myelination (A) or neuroin-
flammation (B). The analysis indicates a statistically significant correlation
between SMDs of non-contrast-enhanced MRI outcomes and SMDs of (re-)
myelination (r = 0.63, p < 0.001). No statistically significant correlation was
found between SMDs of MRI outcomes and neuroinflammation.
Fig. 5. Evaluation of publication bias. Funnel plots for the outcome MRI in-
dicating publication bias. The dashed line represents the standardized mean
difference (SMD) of the summary effect.
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neurodegeneration and MRI. Moreover, no therapies are currently ap-
proved to mitigate neurodegeneration in MS, which is present even
early in the disease course (Filippi et al., 2018; Trapp et al., 1998). A
deeper understanding about certain MR image features and their un-
derlying histopathology could facilitate the choice for adequate out-
comes in clinical trials (Maggi et al., 2014).
For the assessment of therapy efficacy, most publications used a T2
and/or contrast-enhancing lesion burden measure. These outcomes are
also commonly used in the design of clinical trials and thus reflect
sound outcome measures also for preclinical research (van Munster and
Uitdehaag, 2017). It is noteworthy that DWI, including tractography, is
increasingly used in preclinical neuroimaging research and is a popular
choice for determining white matter microstructure in vivo (Jelescu and
Budde, 2017). Hence, DWI has particular relevance for demyelinating
and/or neurodegenerative pathology, both of which are hallmarks of
MS (and to some degree MS animal models) (Lassmann and Bradl,
2016; Trapp et al., 1998). Recent attempts at standardizing DWI
methodology in preclinical research further support its benefit in MS
animal model neuroimaging (Anderson et al., 2020). Yet, the specificity
of DWI findings needs to be further validated in correlative histo-
pathology studies (Budde et al., 2009). Also, a careful choice of imaging
parameters, such as gradient strength, gradient duration and diffusion
time, is key for reliable DWI results (Jelescu and Budde, 2017).
Of note, only a few studies used MRI brain/spinal cord atrophy as
outcome measure, even though this outcome is increasingly being used
in clinical trials. A potential reason for this discrepancy is technical
limitations during post-processing of images, which may impede the
determination of a reliable atrophy rate in smaller-scale brains, such as
from rodents, especially within the mostly brief time frame of animal
studies (Kurniawan, 2018). However, a considerable number of studies
performed longitudinal neuroimaging up to 12 months. Such long-
itudinal assessment of disease processes can greatly support
pathophysiological understanding, particularly in neuroinflammation
and therefore highly dynamic pathology (Maggi et al., 2017).
Finally, visual inspection of the funnel plot and testing of the Egger
regression indicated publication bias, whereby effect sizes are over-
estimated. It has been suggested that publication bias may account for
at least one-third of the efficacy reported in systematic reviews of an-
imal stroke studies (Sena et al., 2010; Van der Worp et al., 2010). Si-
milar overestimations of effect sizes are likely true for other model
diseases, including MS.
5. Limitations
Our review has some limitations. (1) Many key methodological
details of animal studies included in our review were poorly reported.
Unfortunately, this also holds true for many other systematic reviews of
animal studies (Hooijmans et al., 2015) — a situation that seriously
hampers reliable risk of bias assessment. Although this limits our ability
to reliably estimate the validity of the results of the included studies, we
nevertheless included the poorly reported papers in this review because
papers that do not report essential details are not necessarily metho-
dologically impaired (Green and Higgins, 2005). (2) For the meta-ana-
lysis, the number of studies was low, while the variability between the
studies was considerable. This influences the reliability of the conclu-
sions drawn from this systematic review. To account for that, we an-
ticipated heterogeneity by using a random rather than a fixed-effects
model for the meta-analysis. (3) We did not perform post-hoc power-
calculations due to their limited validity (Levine and Ensom, 2001). It is
worth reiterating that sample sizes were small in most of the included
studies, in line with previous findings from a large systematic review in
neuroscience (Button et al., 2013). Small sample sizes imply low power,
which lowers the likelihood that a statistically significant result reflects
a true effect (Marino, 2017).
Table 2
Minimal reporting guidelines on technical MRI aspects.
1) MRI system
• MRI system supplier (e.g. Bruker)
• MR system model (e.g. AVANCE)
• Field strength (e.g. 7 T)
• Gradient performance (e.g. 200 mT/m)
• Coil (e.g. 8-channel phase array coil)
2) Animal anaesthesia
Compound(s) (e.g. ketamine/xylazine)Concentration of compound(s) (e.g. 35 mg/
kg)
Application form (e.g. intramuscular injection)
3) Pulse sequence(s)
• Sequence (e.g. spin echo)
• Purpose of sequence (e.g. measuring T1 lesion burden)
• Weighting (e.g. T1-weighted)
• Echo and repetition time (e.g. 3.5/2000 ms)
• Inversion time (e.g. 900 ms, if applicable)
• Flip angle magnitude (e.g. 15°)
• Acquisition mode (e.g. 3D)
• Acquisition plane (e.g. sagittal, in case of 2D imaging)
• Multi-slice imaging (if applicable)
• Number of echoes (e.g. 16, if applicable)
• Voxel size (e.g. 150 × 150 × 150 µm
3 or 150 × 150 µm2 with slice thickness of
1 mm)
• Matrix size (e.g. 256 × 256)
• Field of view (e.g. 30 × 30 mm
2)
• Number of slices
• Number of signal averages
• Receiver bandwidth (e.g. 25.5 kHz)
• Acquisition time for each sequence and total acquisition time
• Fat saturation (e.g. chemical shift, if applicable)
For magnetization transfer imaging (MTI)
• Saturation power (e.g. 0.9 µT)
• Off-resonance pulse (e.g. 1 kHz)
• Pulse shape (e.g. Gaussian shaped)
• Pulse length (e.g. 0.2 ms)
• Number of pulses (e.g. 20)
• MTR flip angle (e.g. 1045°)
For diffusion-weighted imaging (DWI)
• Pulse gradient strength increment (G, e.g. 5 gauss/cm)
• Diffusion gradient duration (δ, e.g. 10 ms)
• Duration between paired gradients (Δ, e.g. 200 ms)
• b value (e.g. 1124 s/mm
2)
• Maximal q value (e.g. 500 cm
−1)
• Number of directions (e.g. 6)
4) Contrast agent
• Contrast medium (e.g. gadoterate meglumine, including supplier)
• Contrast-medium dose (e.g. 0.3 mmol/kg body weight)
• Application form (e.g. via tail vein catheter)
• Exact time between imaging and application
5) Ex vivo imaging
• Medium for animal perfusion (e.g. 4% formaldehyde)
• Medium for immersion fixation (e.g. 4% formaldehyde)
• Contrast agent for tissue immersion (e.g. gadoteridol)
• Time for immersion fixation (e.g. 24 h)
• Medium during imaging (e.g. Fomblin)
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6. Conclusions
Our systematic review summarizes preclinical studies using MRI in
MS animal models. We show that, whereas preclinically used MRI
outcomes correlate well with underlying measures of (re-)myelination,
reporting on certain technical aspects of MRI acquisition is poor. We
therefore propose minimal, non-onerous reporting guidelines for stu-
dies using MRI in a preclinical setup. These guidelines address the
important problem of insufficient methodological reporting and ac-
companying lack of experimental reproducibility. Taken together,
findings from our study will inform preclinical researchers on adequate
reporting of technical aspects of MRI acquisition. We hope this will
encourage successful replication of future results and, eventually, suc-
cessful bench-to-bedside translation of promising therapeutic ap-
proaches.
Declaration of Competing Interest
The authors declare that they have no known competing financial
interests or personal relationships that could have appeared to influ-
ence the work reported in this paper.
Acknowledgments
This work was supported by grants of the Swiss National Science
Foundation (No. P400PM_183884, to BVI) and by the Intramural
Research Program of the National Institute of Neurological Disorders
and Stroke. We thank Martina Gosteli (University of Zurich) for help
with the literature search. We thank Prof. Carlijn Hooijmans from the
SYstematic Review Center for Laboratory animal Experimentation
(SYRCLE) for support with the meta-analysis. We also thank Louis
Vierne and Karol Szymanowsky for help with data extraction.
Author contribution
BVI, PS, and DSR contributed to the conceptual development of the
project; BVI wrote the manuscript and provided figures; TG, PS, and
DSR critically revised the manuscript and figures; BVI performed the
meta-analysis; MA, NJL, and JL gave critical input to the conceptual
development of the study and the manuscript.
Data availability statement
All data available from the authors upon reasonable request.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.nicl.2020.102371.
References
Amiri, H., de Sitter, A., Bendfeldt, K., Battaglini, M., Gandini Wheeler-Kingshott, C.A.M.,
Calabrese, M., Geurts, J.J.G., Rocca, M.A., Sastre-Garriga, J., Enzinger, C., de Stefano,
N., Filippi, M., Rovira, A., Barkhof, F., Vrenken, H., 2018. Urgent challenges in
quantification and interpretation of brain grey matter atrophy in individual MS pa-
tients using MRI. Neuroimage Clin. 19, 466–475.
Anderson, R.J., Long, C.M., Calabrese, E.D., Robertson, S.H., Johnson, G.A., Cofer, G.P.,
O'Brien, R.J., Badea, A., 2020. Optimizing Diffusion Imaging Protocols for Structural
Connectomics in Mouse Models of Neurological Conditions. Frontiers in physics 8.
Baker, D., Lidster, K., Sottomayor, A., Amor, S., 2014. Two years later: journals are not yet
enforcing the ARRIVE guidelines on reporting standards for pre-clinical animal stu-
dies. PLoS Biol. 12, e1001756.
Budde, M.D., Xie, M., Cross, A.H., Song, S.-K., 2009. Axial diffusivity is the primary
correlate of axonal injury in the experimental autoimmune encephalomyelitis spinal
cord: a quantitative pixelwise analysis. J. Neurosci. 29, 2805–2813.
Button, K.S., Ioannidis, J.P., Mokrysz, C., Nosek, B.A., Flint, J., Robinson, E.S., Munafo,
M.R., 2013. Power failure: why small sample size undermines the reliability of
neuroscience. Nat. Rev. Neurosci. 14, 365–376.
Carp, J., 2012. The secret lives of experiments: methods reporting in the fMRI literature.
Neuroimage 63, 289–300.
Collins, F.S., Tabak, L.A., 2014. Policy: NIH plans to enhance reproducibility. Nature 505,
612–613.
de Vries, R.B., Hooijmans, C.R., Tillema, A., Leenaars, M., Ritskes-Hoitinga, M., 2014.
Updated version of the embase search filter for animal studies. Lab. Anim. 48, 88.
Filippi, M., Bar-Or, A., Piehl, F., Preziosa, P., Solari, A., Vukusic, S., Rocca, M.A., 2018.
Multiple sclerosis. Nat. Rev. Dis. Primers 4, 43.
Freedman, L.P., Cockburn, I.M., Simcoe, T.S., 2015. The economics of reproducibility in
preclinical research. PLoS Biol. 13, e1002165.
Green, S., Higgins, J., 2005. Cochrane handbook for systematic reviews of interventions.
Version.
Higgins, J.P., Thompson, S.G., 2002. Quantifying heterogeneity in a meta-analysis. Stat.
Med. 21, 1539–1558.
Hooijmans, C.R., Geessink, F.J., Ritskes-Hoitinga, M., Scheffer, G.J., 2015. A systematic
review and meta-analysis of the ability of analgesic drugs to reduce metastasis in
experimental cancer models. Pain 156, 1835–1844.
Hooijmans, C.R., Hlavica, M., Schuler, F.A.F., Good, N., Good, A., Baumgartner, L.,
Galeno, G., Schneider, M.P., Jung, T., de Vries, R., Ineichen, B.V., 2019.
Remyelination promoting therapies in multiple sclerosis animal models: a systematic
review and meta-analysis. Sci. Rep. 9, 822.
Hooijmans, C.R., Rovers, M.M., de Vries, R.B., Leenaars, M., Ritskes-Hoitinga, M.,
Langendam, M.W., 2014. SYRCLE's risk of bias tool for animal studies. BMC Med. Res.
Method. 14, 43.
Jelescu, I.O., Budde, M.D., 2017. Design and validation of diffusion MRI models of white
matter. Front. Phys. 5, 61.
Justice, M.J., Dhillon, P., 2016. Using the mouse to model human disease: increasing
validity and reproducibility. Dis. Model Mech. 9, 101–103.
Kilkenny, C., Browne, W.J., Cuthill, I.C., Emerson, M., Altman, D.G., 2010. Improving
bioscience research reporting: the ARRIVE guidelines for reporting animal research.
PLoS Biol. 8, e1000412.
Kurniawan, N.D., 2018. MRI in the study of animal models of neurodegenerative diseases.
Methods Mol. Biol. 1718, 347–375.
Landis, S.C., Amara, S.G., Asadullah, K., Austin, C.P., Blumenstein, R., Bradley, E.W.,
Crystal, R.G., Darnell, R.B., Ferrante, R.J., Fillit, H., 2012. A call for transparent re-
porting to optimize the predictive value of preclinical research. Nature 490, 187–191.
Lassmann, H., Bradl, M., 2016. Multiple sclerosis: experimental models and reality. Acta
Neuropathol.
Levine, M., Ensom, M.H., 2001. Post hoc power analysis: an idea whose time has passed?
Pharmacother. J. Hum. Pharmacol. Drug Therapy 21, 405–409.
Macleod, M.R., Fisher, M., O'Collins, V., Sena, E.S., Dirnagl, U., Bath, P.M., Buchan, A.,
van der Worp, H.B., Traystman, R.J., Minematsu, K., Donnan, G.A., Howells, D.W.,
2009. Reprint: good laboratory practice: preventing introduction of bias at the bench.
J. Cereb. Blood Flow Metab. 29, 221–223.
Macleod, M.R., van der Worp, H.B., Sena, E.S., Howells, D.W., Dirnagl, U., Donnan, G.A.,
2008. Evidence for the efficacy of NXY-059 in experimental focal cerebral ischaemia
is confounded by study quality. Stroke 39, 2824–2829.
Maggi, P., Macri, S.M., Gaitan, M.I., Leibovitch, E., Wholer, J.E., Knight, H.L., Ellis, M.,
Wu, T., Silva, A.C., Massacesi, L., Jacobson, S., Westmoreland, S., Reich, D.S., 2014.
The formation of inflammatory demyelinated lesions in cerebral white matter. Ann.
Neurol. 76, 594–608.
Maggi, P., Sati, P., Massacesi, L., 2017. Magnetic resonance imaging of experimental
autoimmune encephalomyelitis in the common marmoset. J. Neuroimmunol. 304,
86–92.
Marino, M.J., 2017. How often should we expect to be wrong? Statistical power, p values,
and the expected prevalence of false discoveries. Biochem. Pharmacol.
Moher, D., Cook, D.J., Eastwood, S., Olkin, I., Rennie, D., Stroup, D.F., 1999. Improving
the quality of reports of meta-analyses of randomised controlled trials: the QUOROM
statement. Quality of Reporting of Meta-analyses. Lancet 354, 1896–1900.
Moher, D., Schulz, K.F., Altman, D., Group, C., 2001. The CONSORT statement: revised
recommendations for improving the quality of reports of parallel-group randomized
trials. JAMA 285, 1987–1991.
Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P.,
Stewart, L.A., 2015. Preferred reporting items for systematic review and meta-ana-
lysis protocols (PRISMA-P) 2015 statement. Systemat. Rev. 4, 1.
Namer, I.J.S., J.; Poulet, P.; Mauss, Y.; Armspach, J. P.; Eclancher, B.; Chambron, J., 1994.
Hyperbaric oxygen treatment in acute experimental allergic encephalomyelitis.
Contribution of magnetic resonance imaging study. NeuroImage 1, 308-312.
Petersen, R.C., Aisen, P., Beckett, L.A., Donohue, M., Gamst, A., Harvey, D.J., Jack, C.,
Jagust, W., Shaw, L., Toga, A., 2010. Alzheimer's disease neuroimaging initiative
(ADNI): clinical characterization. Neurology 74, 201–209.
Sena, E.S., Van Der Worp, H.B., Bath, P.M., Howells, D.W., Macleod, M.R., 2010.
Publication bias in reports of animal stroke studies leads to major overstatement of
efficacy. PLoS Biol. 8, e1000344.
Steward, O., Balice-Gordon, R., 2014. Rigor or mortis: best practices for preclinical re-
search in neuroscience. Neuron 84, 572–581.
Stewart, W.A.A., E. C., Jr.; Hruby, S.; Hall, L. D.; Paty, D. W., 1991. Magnetic resonance
imaging of experimental allergic encephalomyelitis in primates. Brain 114, 1069-
1096.
Stewart, W.A.A., E. C.; Hruby, S.; Hall, L. D.; Paty, D. W., 1985. Early detection of ex-
perimental allergic encephalomyelitis by magnetic resonance imaging. Lancet 2, 898.
Trapp, B.D., Peterson, J., Ransohoff, R.M., Rudick, R., Mork, S., Bo, L., 1998. Axonal
transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338, 278–285.
Van der Worp, H.B., Howells, D.W., Sena, E.S., Porritt, M.J., Rewell, S., O'Collins, V.,
Macleod, M.R., 2010. Can animal models of disease reliably inform human studies?
PLoS Med. 7, e1000245.
B.V. Ineichen, et al. NeuroImage: Clinical 28 (2020) 102371
9
Van Essen, D.C., Smith, S.M., Barch, D.M., Behrens, T.E., Yacoub, E., Ugurbil, K.,
Consortium, W.-M.H., 2013. The WU-Minn human connectome project: an overview.
Neuroimage 80, 62–79.
van Munster, C.E., Uitdehaag, B.M., 2017. Outcome measures in clinical trials for mul-
tiple sclerosis. CNS Drugs 31, 217–236.
Vesterinen, H.M., Sena, E.S., ffrench-Constant, C., Williams, A., Chandran, S., Macleod,
M.R., 2010. Improving the translational hit of experimental treatments in multiple
sclerosis. Mult Scler 16, 1044-1055.
Waiczies, S., Rosenberg, J.T., Kuehne, A., Starke, L., Delgado, P.R., Millward, J.M., Prinz,
C., Dos Santos Periquito, J., Pohlmann, A., Waiczies, H., Niendorf, T., 2019. Fluorine-
19 MRI at 21.1 T: enhanced spin-lattice relaxation of perfluoro-15-crown-5-ether and
sensitivity as demonstrated in ex vivo murine neuroinflammation. Magma 32, 37–49.
Zwetsloot, P.P., Van Der Naald, M., Sena, E.S., Howells, D.W., IntHout, J., De Groot, J.A.,
Chamuleau, S.A., MacLeod, M.R., Wever, K.E., 2017. Standardized mean differences
cause funnel plot distortion in publication bias assessments. Elife 6.
B.V. Ineichen, et al. NeuroImage: Clinical 28 (2020) 102371
10
